Filtered By:
Drug: Empagliflozin
Education: Conferences
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial
ASN 2016 High Impact Clinical Trial
Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany.
Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk type 2 diabetic patients to examine the impact on the primary composite outcome of nonfatal MI, nonfatal stroke, and cardiovascular death. The secondary renal endpoint (composite of doubling serum creatinine, ESRD, death due to renal ...
Source: Nephrology Now - November 19, 2016 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Trial Results Conference Alert Source Type: research
